EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Less Is More: Developments in Nanotechnology for Antirestenosis Therapies

Chantal M Trepanier iD, Jonah Burke-Kleinman iD, Bradley H Strauss iD, J Paul Santerre iD, Michelle P Bendeck iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023-07 · 43 (7) · 1096-1110

DOI: 10.1161/atvbaha.123.318450 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023-07. Verfasst von Chantal M Trepanier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Engineering (C.M.T., J.P.S.), University of Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Vascular Diseases, Thrombosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 127 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite recent advancements in vascular disease treatments, thrombosis and poor long-term vessel patency remain significant barriers to effective endovascular intervention. Current balloon angioplasty and stenting techniques effectively restore acute blood flow in occluded vessels but have persistent limitations. Damage to the arterial endothelium caused by injury during catheter tracking triggers neointimal hyperplasia and the release of proinflammatory factors leading to increased risk of thrombosis and restenosis. Antirestenotic agents commonly delivered on angioplasty balloons and stents have lowered arterial restenosis rates, but the absence of cell type selectivity significantly delays critical endothelium repair. Targeted delivery of biomolecular therapeutics, coupled with engineered nanoscale excipients, has the potential to redefine cardiovascular interventions by improving long-term efficacy, limiting off-target effects, and reducing costs compared with conventional clinical standards of care. This review analyzes current forms of localized vascular drug delivery, emerging nanoscale therapeutic and excipient strategies, and provides recommendations for future areas of study to advance the treatment of vascular disease through innovations in nanotechnology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, BalloonVascular DiseasesThrombosisHumansStentsConstriction, PathologicNanotechnologyTreatment Outcome

Stichwörter der Autor:innen

coronary artery diseasenanoparticlesnanotechnologyperipheral arterial diseasestents

Autor:innen und Institutionen

  • Institute of Biomedical Engineering (C.M.T., J.P.S.), University of Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine (J.B.-K., M.P.B.), University of Toronto, Ontario, Canada.
  • Schulich Heart Program, Sunnybrook Health Sciences Centre (B.H.S.), University of Toronto, Ontario, Canada.
  • Translational Biology and Engineering Program, Ted Rogers Centre for Heart Research, Toronto, Ontario, Canada (C.M.T., J.B.-K., J.P.S., M.P.B.).

ORCID-Profile: Chantal M Trepanier, Jonah Burke-Kleinman, Bradley H Strauss, J Paul Santerre, Michelle P Bendeck

Zitieren

APA

Trepanier, C. M., Burke-Kleinman, J., Strauss, B. H., Santerre, J. P., & Bendeck, M. P. (2023). Less Is More: Developments in Nanotechnology for Antirestenosis Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(7), 1096-1110. https://doi.org/10.1161/atvbaha.123.318450

Vancouver

Trepanier CM, Burke-Kleinman J, Strauss BH, Santerre JP, Bendeck MP. Less Is More: Developments in Nanotechnology for Antirestenosis Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(7):1096-1110. doi:10.1161/atvbaha.123.318450

BibTeX
@article{Trepanier2023,
  author = {Trepanier, Chantal M and Burke-Kleinman, Jonah and Strauss, Bradley H and Santerre, J Paul and Bendeck, Michelle P},
  title = {Less Is More: Developments in Nanotechnology for Antirestenosis Therapies},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  volume = {43},
  number = {7},
  pages = {1096--1110},
  doi = {10.1161/atvbaha.123.318450}
}
Kostenlos starten →